PRMEHealthcare · BiotechnologyThe 14 Wall Street analysts covering Prime Medicine, Inc. hold a median 12-month price target of $7 — +123.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 40 of 100 as at 14 Oct 2026 — in the lower half.
Consensus tells you what everyone already believes. The model scores Prime Medicine, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (63): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (14): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRME, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +123.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | Chardan Capital | Maintains | Buy | $7.00 |
| 25 Aug 2026 | Chardan Capital | Maintains | Buy | $7.00 |
| 25 Aug 2026 | Chardan Capital | Maintains | Buy | — |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $9.00 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $8.00 |
| 29 June 2026 | HC Wainwright & Co. | Upgrade | Buy | $8.00 |
| 29 June 2026 | HC Wainwright & Co. | Upgrade | Buy | — |
| 12 Mar 2026 | Oppenheimer | Initiates | Outperform | — |
| 23 Dec 2025 | LifeSci Capital | Initiates | Outperform | — |
| 11 Nov 2025 | Citigroup | Maintains | Neutral | — |
| 10 Nov 2025 | Chardan Capital | Maintains | Buy | — |
| 12 Aug 2025 | Citigroup | Maintains | Neutral | — |
| 8 Aug 2025 | Chardan Capital | Maintains | Buy | — |
| 27 May 2025 | Citigroup | Downgrade | Neutral | — |
| 20 May 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 20 May 2025 | JMP Securities | Maintains | Market Outperform | — |
| 20 May 2025 | JP Morgan | Downgrade | Neutral | — |
| 19 May 2025 | Chardan Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRME appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 14 Oct 2026, Prime Medicine, Inc. returned −47.7% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 3% of US stocks
Cheaper than 7% of US stocks
Cheaper than 77% of US stocks
Higher than 35% of US stocks
Higher than 40% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
Higher than 4% of US stocks
Higher than 9% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Prime Medicine, Inc. has a market value of $602.2M and an enterprise value of $608.0M.
Revenue in the twelve months to 30 June 2026: $4.1M. The latest quarter grew 3.5% year on year.
Net income over the same four quarters: −$187.9M, a −4613.1% net margin.
Free cash flow in the twelve months to 30 June 2026: −$156.8M.
Trailing P/E: −2.3×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Prime Medicine, Inc. employs 146 people — $28K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Prime Medicine, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Prime Medicine (PRME) shares rose nearly 26% in a month. The cited factor was FDA clearance for PM647 and PM577a, advancing their clinical debut and the company’s gene-editing pipeline.
Why it matters — The FDA clearance and the programs’ clinical progress are relevant developments for investors following PRME’s pipeline.
The article argues that fourth-quarter S&P 500 returns have historically been strong, particularly after midterm election years, and names PRME among small-cap healthcare and biotech stocks viewed as potential breakout candidates.
Why it matters — PRME is highlighted as a possible early breakout candidate, alongside a broader market-seasonality thesis and mention of institutional interest and analyst targets.
Prime Medicine announced that the first patient has been dosed in a global Phase 1/2 clinical trial of PM577a, a first-in-human study evaluating the therapy's safety, tolerability, and initial clinical efficacy. PM577a is designed as a one-time treatment to correct the H1069Q mutation in ATP7B, the most common Wilson disease-causing mutation in North America and Europe.
Why it matters — This milestone advances Prime Medicine's PM577a candidate into the clinic, marking meaningful clinical progress for its lead asset targeting a prevalent Wilson disease mutation.
Prime Medicine announced that the FDA cleared its Investigational New Drug (IND) application for PM647, a gene editing therapy candidate. The company is a biotechnology firm developing one-time curative genetic therapies.
Why it matters — FDA clearance of the IND allows Prime Medicine to move PM647 toward clinical study, a key regulatory milestone for the company's therapy pipeline.
Prime Medicine announced that the U.S. FDA has cleared its Investigational New Drug application for PM647, a treatment for Alpha-1 Antitrypsin Deficiency. This clearance builds on recent regulatory clearance for PM577a and reflects continued execution across the company's liver franchise, with initial clinical data expected in 2027.
Why it matters — This regulatory clearance advances Prime Medicine's liver pipeline and signals continued momentum and modularity in its development program, giving PRME watchers a concrete milestone to track toward clinical data in 2027.
The 14 Wall Street analysts covering Prime Medicine, Inc. have a median 12-month price target of $7, with estimates ranging from $4.25 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Prime Medicine, Inc., 11 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prime Medicine, Inc. 40 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 14 Oct 2026, Prime Medicine, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (63 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +123.6% from the last close, and Ticker Nerd's factor model ranks Prime Medicine, Inc. 40 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Prime Medicine, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRME are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4.25 to $11 over the next 12 months.
Prime Medicine, Inc. returned -47.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA.
The most recent item we track (Zacks Investment Research, 12 Oct 2026): "Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why". Prime Medicine (PRME) shares rose nearly 26% in a month. The cited factor was FDA clearance for PM647 and PM577a, advancing their clinical debut and the company’s gene-editing pipeline.
Prime Medicine, Inc. is a biotechnology company focused on developing genetic medicines through its Prime Editing platform, a gene-editing technology designed to make precise changes to DNA. The company is building therapies intended to address diseases caused by defined genetic alterations, with research programs spanning hematology, immunology and oncology, liver, lung, ocular, and neuromuscular conditions. Its current work centers on investigational, pre-commercial product candidates and platform capabilities that support targeted genetic correction across multiple tissues and disease areas. Prime Medicine, Inc. plays a specialized role in the broader genetic medicines market by advancing next-generation editing approaches aimed at expanding the reach of precision therapeutics for serious inherited and acquired diseases.
CEO Dr. Allan Reine M.D. · 146 employees · United States · https://primemedicine.com
